{"product_id":"gmab-bcg-matrix","title":"(GMAB) Genmab A\/S BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Genmab A\/S BCG Matrix is a company-specific tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs for strategy, research, and capital allocation. The page already shows a real preview of the analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmivantamab 2 approved cancer settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmivantamab has 2 approved cancer settings: advanced NSCLC and gastric or esophageal cancer. That label breadth gives Genmab A\/S more runway than a single-disease asset, with 2 major oncology markets instead of 1.\u003c\/p\u003e\n\u003cp\u003eUptake can still rise as earlier-line combinations move in, so the franchise is still in growth mode.\u003c\/p\u003e\n\u003cp\u003eIn BCG terms, this fits a Star: high-growth use case with expanding commercial potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpcoritamab 2 hematology settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpcoritamab is a Star in Genmab A\/S’s BCG mix: it is approved for relapsed\/refractory large B-cell lymphoma, while the bispecific antibody class is still scaling fast, with high unmet need and strong clinical adoption signals. In EPCORE NHL-1, the overall response rate was 63% and complete response was 39%, but commercial share is still early, so Genmab keeps support spend high to build uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKesimpta ofatumumab MS franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKesimpta stayed a top Genmab royalty engine through Novartis, with 2025 sales above $2bn and repeat monthly dosing in relapsing MS. The chronic treatment base keeps demand sticky, so it fits the Stars bucket. Strong growth has kept it in the portfolio’s top tier.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTeprotumumab 1 thyroid eye disease market leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeprotumumab is the first approved therapy for thyroid eye disease, and that first-mover edge keeps it the market leader in a niche specialty field. Tepezza generated about $1.9 billion in 2025 sales, showing strong demand despite a limited patient pool. With thyroid eye disease affecting roughly 50,000 to 100,000 people in the U.S. and diagnosis still improving, the franchise can keep growing as treatment access expands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst approved thyroid eye disease therapy\u003c\/li\u003e\n\u003cli\u003e2025 sales: about $1.9 billion\u003c\/li\u003e\n\u003cli\u003eStrong first-mover brand visibility\u003c\/li\u003e\n\u003cli\u003eGrowth tied to higher diagnosis rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTisotumab vedotin cervical cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTisotumab vedotin is a Star for Genmab A\/S: it is approved for recurrent or metastatic cervical cancer, a high-unmet-need solid tumor with about 661,000 new cases and 348,000 deaths worldwide in 2022. Growth still depends on broader uptake and label expansion, but the niche is real and clinically hard to serve.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved for recurrent\/metastatic cervical cancer\u003c\/li\u003e\n\u003cli\u003eTargets a high-unmet-need niche\u003c\/li\u003e\n\u003cli\u003eUpside depends on uptake and expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab’s Star Assets Are Scaling Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S’s Stars are amivantamab, epcoritamab, Kesimpta, teprotumumab, and tisotumab vedotin. Each sits in a growing market with clear clinical demand: 2025 sales topped $2.0bn for Kesimpta and about $1.9bn for teprotumumab, while amivantamab and epcoritamab still have expansion upside. That mix fits BCG Star logic: high growth, rising adoption, and continued spend to scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKesimpta\u003c\/td\u003e\n\u003ctd\u003e2025 sales \u0026gt;$2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeprotumumab\u003c\/td\u003e\n\u003ctd\u003e2025 sales ~$1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpcoritamab\u003c\/td\u003e\n\u003ctd\u003eEarly growth, 63% ORR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGenmab A\/S BCG Matrix spots which drugs to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Genmab A\/S BCG Matrix to quickly spot cash cows, stars, and drags.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Genmab A\/S, making key assumptions easier to verify and decisions easier to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX multiple myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDARZALEX (daratumumab) is still Genmab A\/S’s biggest royalty engine, with Johnson \u0026amp; Johnson reporting 2024 worldwide sales of about $11.7 billion. The multiple myeloma market is mature, but DARZALEX still holds a top share and keeps generating strong cash for Genmab. Even if growth slows, this brand remains a classic cash cow: high sales, low reinvestment, and durable royalty income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX AL amyloidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDARZALEX generated about $11.7 billion in 2024 global sales, and the AL amyloidosis label adds a smaller but steady revenue stream for Genmab A\/S through royalties. This is a niche specialty use, so new competition is limited and the demand base stays durable. In BCG terms, it behaves like a cash cow: mature, protected, and highly cash-generative.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX non-MM blood cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDARZALEX keeps widening Genmab A\/S's installed base beyond multiple myeloma, with approved use in AL amyloidosis and a deep physician track record. J\u0026amp;J reported 2024 DARZALEX sales of about USD 11.7 billion, showing scale that supports durable royalty flow for Genmab A\/S. Growth is slower than launch years, but share stays very high because the brand is entrenched and evidence-backed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOfatumumab CLL legacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOfatumumab CLL is a legacy anti-CD20 asset that dates back to its 2009 FDA approval, and it now sits far behind newer growth drivers. Genmab’s Kesimpta franchise has become the clear royalty engine, while the CLL version acts more like a harvest asset than a growth story. That makes this Cash Cow useful for steady cash, but not for meaningful top-line expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2009 approval; now a mature brand.\u003c\/li\u003e\n\u003cli\u003eGrowth lags Kesimpta by a wide margin.\u003c\/li\u003e\n\u003cli\u003eSupports cash flow, not expansion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMature collaboration royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab A\/S still leans on partnered antibody economics: FY2025 cash came mainly from royalties and milestones tied to external programs, so it can turn drug wins into income without heavy selling spend. That fits a BCG Cash Cow profile: mature, low-growth, and cash-generative rather than capital-hungry. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties convert partner sales into cash.\u003c\/li\u003e\n\u003cli\u003eMilestones need limited promotion spend.\u003c\/li\u003e\n\u003cli\u003eCore value comes from mature antibody deals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX Powers Genmab’s Cash Cow Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDARZALEX is Genmab A\/S’s core Cash Cow: Johnson \u0026amp; Johnson reported about USD 11.7 billion in 2024 sales, and Genmab A\/S keeps earning royalties with little reinvestment. Ofatumumab CLL is also mature, but it is a much smaller legacy asset. These products fit a low-growth, high-cash BCG profile.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX\u003c\/td\u003e\n\u003ctd\u003eUSD 11.7B 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOfatumumab CLL\u003c\/td\u003e\n\u003ctd\u003e2009 FDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eGenmab A\/S Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact Genmab A\/S BCG Matrix document you'll receive after purchase. What you see here is the same fully formatted file, with no demo content or hidden changes. Once purchased, the full report is instantly available for download, editing, or sharing. It's a ready-to-use strategic analysis built for professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArzerra legacy CLL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArzerra legacy CLL is Genmab A\/S's old intravenous ofatumumab franchise, first approved in 2009. By end-2025, the CLL market is led by BTK and BCL2 therapies, so Arzerra's share is minimal and still fading. It fits the BCG \"dog\" box: low growth, low share, and no real strategic pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCamidanlumab tesirine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCamidanlumab tesirine remains a development-stage asset, with mixed clinical results in relapsed or refractory Hodgkin lymphoma and only early work in solid tumors. With no approved indication or disclosed product revenue, its near-term commercial visibility is still low. That makes it a weak BCG fit and a poor user of Genmab A\/S capital in the short run.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePRV-015 Phase 2 celiac\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePRV-015 Phase 2 celiac is a Dog in Genmab A\/S’s BCG view: it has no commercial share and sits in a selective market with no approved disease-modifying therapy. Celiac disease affects about 1% of people worldwide, but Phase 2 assets only gain value if they show clear, durable symptom and biopsy benefit. Without strong data, PRV-015 stays a low-priority, high-risk asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLu AF82422 Phase 2 MSA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLu AF82422 in Phase 2 for multiple system atrophy is a high-risk \"question mark\" in Genmab A\/S's BCG Matrix. The program has zero market share today, no approved MSA therapy, and approval still depends on a long, uncertain clinical path. If it works, the upside is large; in 2025\/2026, the revenue contribution is still 0.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2 only\u003c\/li\u003e\n\u003cli\u003eMSA unmet need is severe\u003c\/li\u003e\n\u003cli\u003eMarket share is zero\u003c\/li\u003e\n\u003cli\u003eGrowth is still hypothetical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJNJ-64007957 and JNJ-64407564 myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJNJ-64007957 (teclistamab) and JNJ-64407564 (talquetamab) sit in a crowded multiple myeloma field with CAR-Ts, antibody-drug conjugates, and other bispecifics already launched. J\u0026amp;J has already pushed both into a mature, highly competitive class, so Genmab’s visible share is limited and the upside looks low relative to the number of rivals.\u003c\/p\u003e\n\u003cp\u003eIn BCG terms, that mix of low certainty and weak share fits Dogs. The class is crowded, switching costs are high, and leadership is already set by larger franchises with broader sales reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh competition in multiple myeloma\u003c\/li\u003e\n\u003cli\u003eLow visible share for Genmab\u003c\/li\u003e\n\u003cli\u003eLimited BCG growth fit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab’s Dogs: Legacy Assets Losing Ground\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S Dogs are mostly legacy or pre-revenue assets with little 2025\/2026 share. Arzerra is the clearest Dog: a 2009 CLL product in a market now led by BTK and BCL2 drugs, so its value keeps shrinking. PRV-015 and camidanlumab tesirine also stay weak, with no approved revenue and limited proof. JNJ-64007957 and JNJ-64407564 face a crowded myeloma field, so upside looks capped.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\/2026 status\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArzerra\u003c\/td\u003e\n\u003ctd\u003eLegacy CLL, fading share\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRV-015\u003c\/td\u003e\n\u003ctd\u003ePhase 2, no sales\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCamidanlumab\u003c\/td\u003e\n\u003ctd\u003eEarly stage, no sales\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMim8 haemophilia A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMim8 haemophilia A sits in Question Marks because it targets a large, chronic need: haemophilia A affects about 1 in 5,000 male births. If efficacy and dosing convenience hold up, the commercial upside could be strong. As of end-2025, it still needs scale and broader adoption to prove that case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGEN1047 solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGEN1047 is an early solid-tumor bispecific in Genmab A\/S’s pipeline, so it sits in the Question Mark box: high-growth space, tiny current share. The solid-tumor bispecific market is expanding fast, but GEN1047 has no meaningful commercial scale yet, so value depends on late-stage proof. It is a clear invest-or-drop call, with upside only if clinical data and partner support keep funding it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDuoBody-PD-L1x4-1BB solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDuoBody-PD-L1x4-1BB in solid tumors sits in the BCG Question Mark box: the addressable market is huge, with solid tumors making up about 90% of adult cancers, but the program still has no commercial proof.\u003c\/p\u003e\n\u003cp\u003eIts value depends on clinical data showing clear efficacy and tolerability versus the high failure risk typical in immuno-oncology.\u003c\/p\u003e\n\u003cp\u003eUntil Genmab A\/S can turn early promise into response and survival gains, this stays a high-potential, high-risk bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDuoBody-CD40x4-1BB solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDuoBody-CD40x4-1BB is a Genmab solid-tumor immune agonist in a crowded, fast-growing oncology niche. Its addressable market is large, but Genmab has no commercial share here yet, so it fits a Question Mark in BCG terms.\u003c\/p\u003e\n\u003cp\u003eIf clinical data turn strong, the asset could matter a lot; if not, it stays a cash sink. The global oncology market was about $225 billion in 2024 and keeps expanding, which supports the upside case.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth segment\u003c\/li\u003e\n\u003cli\u003eZero current revenue share\u003c\/li\u003e\n\u003cli\u003eBig upside, high risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHexaBody-CD38 and DuoHexaBody-CD37\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHexaBody-CD38 and DuoHexaBody-CD37 stay Question Marks because they are still in clinical development, but both target malignant blood cancers, a field that makes up about 10% of new global cancer cases. Genmab A\/S already has deep hematology know-how, so these assets fit its core science and could matter if efficacy turns into approvals.\u003c\/p\u003e\n\u003cp\u003eUntil late-stage data and regulatory wins arrive, they remain high-potential, high-risk bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore hematology fit\u003c\/li\u003e\n\u003cli\u003eApproval risk still high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab’s High-Upside Bets Face Data Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab A\/S Question Marks are high-upside, low-share bets: Mim8, GEN1047, DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, HexaBody-CD38, and DuoHexaBody-CD37 all sit in large, growing markets but still lack commercial proof. Hematology and oncology support the thesis, yet each asset remains data-driven and funding-sensitive.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMim8\u003c\/td\u003e\n\u003ctd\u003eQM\u003c\/td\u003e\n\u003ctd\u003e~1\/5,000 male births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGEN1047\u003c\/td\u003e\n\u003ctd\u003eQM\u003c\/td\u003e\n\u003ctd\u003eEarly solid tumor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234430034185,"sku":"gmab-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gmab-bcg-matrix.webp?v=1785720035","url":"https:\/\/dcfanalyst.com\/products\/gmab-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}